By Counterforce Health Team in Naglazyme (galsulfase) —

How to Renew Naglazyme (Galsulfase) Coverage with Cigna in Georgia: Timeline, Documents, and Emergency Bridge Options

Answer Box: Renewing Naglazyme (Galsulfase) Coverage with Cigna in Georgia

Start your Naglazyme renewal 2-3 weeks before your current prior authorization expires. Cigna requires annual renewal with documented clinical response (6-minute walk test improvements, reduced urinary GAG levels) and specialist confirmation. Submit through Express Scripts or your prescriber's portal. If coverage lapses, contact BioMarin RareConnections (1-800-NAGLAZYME) for emergency supply while pursuing expedited appeals through Georgia's external review process (60-day deadline). First step: Check your PA expiration date in myCigna.com and gather your latest functional assessments.

Table of Contents

  1. Renewal Triggers: When to Start the Process
  2. Evidence Update: What Cigna Needs to See
  3. Renewal Packet: Required Documents
  4. Timeline: Submission to Decision
  5. If Coverage Lapses: Emergency Bridge Options
  6. Annual Changes: What to Monitor
  7. Personal Tracker: Staying Organized
  8. Appeals Process for Georgia Residents

Renewal Triggers: When to Start the Process

Timing Windows

Standard renewal: Begin 2-3 weeks before your current prior authorization expires. Cigna typically requires annual renewal for Naglazyme, though some plans may require renewal every 6 months.

Early renewal triggers:

  • Declining functional capacity despite treatment
  • New insurance plan or formulary changes
  • Dosage adjustments needed
  • Infusion site changes (home to clinic or vice versa)
Tip: Set a calendar reminder 60 days before expiration to gather documents, and another at 30 days to submit the renewal request.

Signs You Should Start Early

  • Your last 6-minute walk test showed decreased distance
  • Increased respiratory symptoms or cardiac issues
  • New MRI findings suggesting disease progression
  • Insurance plan changes announced for the upcoming year

Evidence Update: What Cigna Needs to See

Response to Therapy Documentation

Cigna requires objective evidence that Naglazyme continues to provide clinical benefit. Based on similar enzyme replacement therapy policies, expect these requirements:

Functional Assessments:

  • 6-minute walk test (6MWT): Distance maintained or improved from baseline
  • 12-minute walk test (12MWT): For patients with rapid progression
  • 3-minute stair climb test (3-MSC): Number of stairs climbed in 3 minutes
  • Urinary GAG levels: Reduction from pre-treatment baseline (typically 76% reduction indicates good response)

Clinical Documentation:

  • Specialist notes from past 12 months
  • Infusion tolerance records
  • Cardiac and pulmonary function tests
  • Growth measurements (for pediatric patients)
Note: Studies show Naglazyme typically improves 6MWT by +75 meters (80%) at 48 weeks, with sustained benefits over an average of 6.8 years of treatment.

Adverse Events and Adherence

Document any infusion reactions and how they're managed:

  • Premedication protocols used
  • Infusion rate adjustments
  • Any treatment interruptions and reasons
  • Overall adherence to weekly dosing schedule

Renewal Packet: Required Documents

Must-Include Documents

Document Type What to Include Where to Get It
Specialist Letter Current clinical status, functional improvements, treatment goals MPS specialist or metabolic geneticist
Lab Results Recent urinary GAG levels, enzyme activity Hospital lab or specialty lab
Functional Tests 6MWT, 12MWT, or 3-MSC results from past 6 months Physical therapy or specialist office
Insurance Information Current member ID, group number, PA history myCigna.com or insurance card
Prescription Updated Rx with current dosing (1 mg/kg weekly IV) Prescribing physician

Letter of Medical Necessity Structure

Your specialist should include:

  1. Diagnosis confirmation: MPS VI with enzyme deficiency or genetic testing
  2. Treatment history: Duration on Naglazyme, previous therapies tried
  3. Clinical response: Specific improvements in walking capacity, stair climbing, GAG levels
  4. Medical necessity: Why continued treatment is essential
  5. Alternative therapies: Why other options aren't suitable (no alternatives exist for MPS VI)

Timeline: Submission to Decision

Standard Process

Step Timeline Action Required
Submission 2-3 weeks before expiration Submit via Express Scripts portal or prescriber
Initial Review 3-5 business days Cigna reviews for completeness
Medical Review 7-14 business days Clinical team evaluates medical necessity
Decision Up to 30 calendar days total Approval or denial notification

Expedited Process

For urgent situations (current supply running out, clinical deterioration):

  • Timeline: 72 hours for decision
  • Requirements: Physician letter documenting urgent medical need
  • Submission: Call Cigna member services and request expedited review

If Coverage Lapses: Emergency Bridge Options

Immediate Actions

1. Contact BioMarin RareConnections

  • Phone: 1-800-NAGLAZYME (1-800-624-5299) or 1-866-906-6100
  • Services: Emergency supply, financial assistance, insurance navigation
  • Available: Compassionate use programs for coverage gaps

2. Specialty Pharmacy Support

  • Accredo: Contact through myCigna.com or 1-800-835-3784
  • Express Scripts: May provide temporary supply pending appeal
  • Request emergency dispensing while appeal is processed

3. Healthcare Provider Options

  • Hospital compassionate use protocols
  • Infusion center emergency supplies
  • Physician samples (if available)

Bridge Therapy Considerations

Important: No alternative enzyme replacement therapy exists for MPS VI. Naglazyme (galsulfase) is the only FDA-approved ERT for this condition.

Supportive care during gaps:

  • Continue respiratory and cardiac monitoring
  • Maintain physical and occupational therapy
  • Monitor for symptom progression
  • Prepare for potential infusion reaction protocol review when restarting

Annual Changes: What to Monitor

Formulary Updates

Cigna updates formularies annually (January 1) and may make mid-year changes:

  • Tier placement: Naglazyme typically remains on specialty tiers (Tier 4 or 5)
  • Prior authorization requirements: May change annually
  • Quantity limits: Dosing restrictions based on weight
  • Site of care requirements: Home vs. infusion center policies

Plan Design Shifts

2024-2025 Georgia Changes:

  • No documented tier shifts for Naglazyme in available Cigna Georgia formularies
  • Specialty drug PA requirements remain consistent
  • Express Scripts continues as primary specialty pharmacy

What to verify annually:

  • Check updated formulary at myCigna.com
  • Review Evidence of Coverage (EOC) for specialty pharmacy rules
  • Confirm infusion site coverage policies

Personal Tracker: Staying Organized

Key Dates to Track

  • Current PA expiration date: ___________
  • Next functional assessment due: ___________
  • Last urinary GAG test: ___________
  • Annual formulary review: January 1
  • Specialist appointment: ___________

Document Checklist

  • Current insurance cards and member ID
  • Complete medication history and dosing
  • Recent lab results (GAG levels, enzyme activity)
  • Functional assessment results (6MWT, stair climb)
  • Specialist visit notes from past 12 months
  • Infusion reaction logs and management protocols

Appeals Process for Georgia Residents

Internal Appeals with Cigna

First Level:

  • Timeline: Submit within 180 days of denial
  • Decision time: 30 calendar days (72 hours if expedited)
  • Submission: myCigna.com, phone (1-800-CIGNA24), or mail

Second Level:

  • Timeline: 60 days after first-level denial
  • Decision time: 30 calendar days
  • Additional evidence: Can submit new clinical information

Georgia External Review

If internal appeals fail, Georgia residents have strong external review rights:

Eligibility: Denials based on medical necessity, experimental/investigational determinations Timeline: Must request within 60 days of final internal denial Process: Free review by independent physicians in the same specialty Contact: Georgia Office of Commissioner of Insurance and Fire Safety

  • Phone: 1-800-656-2298
  • Website: oci.ga.gov (verify current forms and process)

Expedited external review: Available for urgent situations, decided within 72 hours

From our advocates: We've seen families successfully bridge 3-week coverage gaps through BioMarin's emergency supply program while pursuing expedited appeals. The key is acting immediately when you receive a denial and having all clinical documentation ready to submit. This is a composite example based on common scenarios, not a guarantee of outcomes.

Counterforce Health helps patients and clinicians navigate complex prior authorization renewals for specialty medications like Naglazyme. Our platform analyzes denial letters, identifies specific coverage criteria, and generates evidence-backed appeals tailored to each payer's requirements. By automating the appeals process and providing targeted clinical documentation, we help reduce coverage gaps and improve approval rates for essential treatments. Learn more about our prior authorization support services.

FAQ: Common Renewal Questions

Q: How long does Cigna take to process a Naglazyme renewal? A: Standard renewals take up to 30 calendar days. Expedited reviews (for urgent medical situations) are processed within 72 hours.

Q: What if my functional tests show decline despite treatment? A: Document any factors that might explain the decline (illness, medication changes, progression of other MPS VI symptoms). Your specialist should explain why continued treatment remains medically necessary.

Q: Can I switch from home infusion to clinic during renewal? A: Yes, but notify Cigna of the site-of-care change as it may affect coverage requirements and prior authorization.

Q: What if Cigna changes formulary tiers for 2025? A: Current approvals typically continue until expiration. If tier changes increase costs, request a formulary exception through your prescriber.

Q: Does step therapy apply to Naglazyme renewals? A: Unlikely for established patients, as no therapeutic alternatives exist for MPS VI. New patients may need to document why other supportive treatments aren't sufficient.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance company for personalized guidance. Coverage policies and requirements may change; verify current information with official sources. For additional help with insurance appeals in Georgia, contact Counterforce Health or the Georgia Department of Insurance Consumer Services at 1-800-656-2298.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.